参考文献/References:
[1] American Diabetes Association. Diagnosis and classification of diabetes mellitus[J].Diabetes Care,2012,35(Suppl 1):S64-S71.
[2] Nathan DM,DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview[J].Diabetes Care,2014,37(1):9-16.DOI:10.2337/dc13-2112.
[3] Budipitojo T,Fibrianto YH,Mulyani GT.The types of endocrine cells in the pancreas of Sunda porcupine(Hystrix javanica)[J].Vet World,2016,9(6):563-567.DOI:10.14202/vetworld.2016.563-567.
[4] Lefèbvre P.Ketosis-prone atypical diabetes: glucagon is there, too[J].Diabetes Care,2013,36(1):8-10.DOI:10.2337/dc12-1696.
[5] Taborsky GJ Jr.The physiology of glucagon[J].J Diabetes Sci Technol,2010,4(6):1338-1344.DOI:10.1177/193229681000 400607.
[6] Müller WA,Faloona GR,Unger RH. Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance[J].Am J Med,1973,54(1):52-57.
[7] Fredheim S,Andersen ML,P rksen S,et al. The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes[J].Diabetologia,2015,58(4):828-834.DOI:10.1007/s00125-014-3486-3.
[8] Weinstock RS,Xing D,Maahs DM,et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry[J].J Clin Endocrinol Metab,2013,98(8):3411-3419. DOI:10.1210/jc.2013-1589.
[9] Ranjan A,Schmidt S,Madsbad S,et al. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes[J].Diabetes Obes Metab,2016,18(4):410-418. DOI:10.1111/dom.12627.
[10] Christensen M,Calanna S,Sparre-Ulrich AH,et al.Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes[J].Diabetes,2015,64(1):72-78.DOI:10.2337/db14-0440.
[11] Rickels MR,Ruedy KJ,Foster NC,et al. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study[J].Diabetes Care,2016,39(2):264-270.DOI:10.2337/dc15-1498.
[12] Sherr JL,Ruedy KJ,Foster NC,et al.Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes[J].Diabetes Care,2016,39(4):555-562.DOI:10.2337/dc15-1606.
[13] Solloway MJ,Madjidi A,Gu C,et al.Glucagon couples hepatic amino acid catabolism to mTOR-dependent regulation of α-cell mass[J].Cell Rep,2015,12(3):495-510.DOI:10.1016/j.celrep.2015.06.034.
[14] Larger E,Wewer Albrechtsen NJ,Hansen LH,et al. Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation[J].Endocrinol Diabetes Metab Case Rep,2016,2016.pii:16-0081.DOI:10.1530/EDM-16-0081.
[15] Lee Y,Wang MY,Du XQ,et al. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice[J].Diabetes,2011,60(2):391-397.DOI:10.2337/db10-0426.
[16] Damond N, Thorel F, Moyers JS,et al. Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist[J].Elife,2016,5. pii:e13828. DOI:10.7554/eLife.13828.
[17] Jun LS, Millican RL, Hawkins ED,et al. Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production[J].Diabetes,2015,64(3):819-827. DOI:10.2337/db14-1052.
[18] Wang MY,Yan H,Shi Z,et al.Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway[J].Proc Natl Acad Sci U S A,2015,112(8):2503-2508. DOI:10.1073/pnas.1424934112.
[19] Fava GE,Dong EW,Wu H.Intra-islet glucagon-like peptide 1[J].J Diabetes Complications,2016,30(8):1651-1658. DOI:10.1016/j.jdiacomp.2016.05.016.
[20] Kawamori D,Shirakawa J,Liew CW,et al. GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice[J].Diabetologia,2017,60(8):1442-1453. DOI:10.1007/s00125-017-4303-6.
[21] Zibar K,C'uc'a JK,Blaslov K,et al. Difference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes mellitus patients and healthy controls[J].Ann Clin Biochem,2015,52(Pt 2):220-225. DOI:10.1177/0004563214544709.
[22] Harris KB,Boland CL.Adjunctive role of glucagon-like peptide-1 receptor agonists in the management of type 1 diabetes mellitus[J].Pharmacotherapy,2016,36(9):1011-1020. DOI:10.1002/phar.1804.
[23] Garg M,Ghanim H,Kuhadiya ND,et al. Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes[J].Diabetes Obes Metab,2017,19(9):1306-1311. DOI:10.1111/dom.12944.
[24] Schopman JE,Hoekstra JB,Frier BM,et al. Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study[J].Diabetes Obes Metab,2015,17(6):546-553.DOI:10.1111/dom.12453.
[25] Ding L,Gysemans CA,Stangé G,et al. Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice[J].PLoS One,2014,9(9):e107935. DOI:10.1371/journal.pone.0107935.
[26] Hieronymus L,Griffin S.Role of amylin in type 1 and type 2 diabetes[J].Diabetes Educ,2015,41(1 Suppl):47S-56S. DOI:10.1177/0145721715607642.
[27] Weinzimer SA,Sherr JL,Cengiz E,et al.Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes[J].Diabetes Care,2012,35(10):1994-1999.DOI:10.2337/dc12-0330.
[28] Hassan K, Heptulla RA. Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus[J].Pediatr Diabetes,2009,10(4):264-268.DOI:10.1111/j.1399-5448.2008.00490.x.
[29] Herrmann K,Frias JP,Edelman SV,et al.Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy[J].Postgrad Med,2013,125(3):136-144.DOI:10.3810/pgm.2013.05.2635.
[30] Xiong Y,Guo J,Candelore MR,et al.Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine(MK-0893)for the treatment of type Ⅱ diabetes[J].J Med Chem,2012,55(13):6137-6148.DOI:10.1021/jm300579z.
相似文献/References:
[1]袁扬,孙子林.PANDER与β细胞凋亡[J].国际内分泌代谢杂志,2007,(04):253.
[2]刘媛 刘超.1型糖尿病青少年儿童心理行为问题研究进展[J].国际内分泌代谢杂志,2015,(01):63.[doi:10.3760/cma.j.issn.1673-4157.2015.01.016]
Liu Yuan,Liu Chao..Psychological problems in adolescents and children with type 1 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(01):63.[doi:10.3760/cma.j.issn.1673-4157.2015.01.016]
[3]王思倩,吴锦丹.肠促胰素对1型糖尿病患者血糖及胰岛功能的影响[J].国际内分泌代谢杂志,2015,(03):196.[doi:10.3760/cma.j.issn.1673-4157.2015.03.015]
Wang Siqian,Wu Jindan..Effects of incretin on blood glucose and islet function in type 1 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(01):196.[doi:10.3760/cma.j.issn.1673-4157.2015.03.015]
[4]李亚兰,项洁,卜瑞芳.1型糖尿病的DiaPep277免疫治疗[J].国际内分泌代谢杂志,2014,(03):169.[doi:10.3760/cma.j.issn.1673-4157.2014.03.007]
Li Yalan,Xiang Jie,Bu Ruifang..Immunotherapy with DiaPep277 peptide in type 1 diabetes[J].International Journal of Endocrinology and Metabolism,2014,(01):169.[doi:10.3760/cma.j.issn.1673-4157.2014.03.007]
[5]陈晔,李艳玲,王坚.天然免疫细胞在1型糖尿病中的作用[J].国际内分泌代谢杂志,2014,(03):184.[doi:10.3760/cma.j.issn.1673-4157.2014.03.011]
Chen Ye,Li Yanling,Wang Jian..Role of innate immune cells in type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2014,(01):184.[doi:10.3760/cma.j.issn.1673-4157.2014.03.011]
[6]蔡芸莹 苏恒.1型糖尿病的非胰岛素治疗[J].国际内分泌代谢杂志,2015,(06):388.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.007]
Cai Yunying,Su Heng.Noninsulin management in type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(01):388.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.007]
[7]朱婧 蒋晓红 项守奎 许晨 华飞.1型糖尿病患者尿酸水平与血脂异常的
相关性研究[J].国际内分泌代谢杂志,2020,40(01):16.[doi:10.3760/cma.j.issn.1673-4157.2020.01.004]
Zhu Jing,Jiang Xiaohong,Xiang Shoukui,et al.Correlation between uric acid level and dyslipidemia in patients with type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2020,40(01):16.[doi:10.3760/cma.j.issn.1673-4157.2020.01.004]
[8]周小海,安晔,王小玲,等.1型糖尿病合并非酒精性脂肪性肝病与慢性肾脏病的关系[J].国际内分泌代谢杂志,2021,41(04):339.[doi:10.3760/cma.j.cn121383-20200713-07032]
Zhou Xiaohai,An Ye,Wang Xiaoling,et al.Relationship between nonalcoholic fatty liver disease and chronic kidney disease in patients with type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2021,41(01):339.[doi:10.3760/cma.j.cn121383-20200713-07032]
[9]陈双,杨涛,顾愹.1型糖尿病的诊断与免疫治疗[J].国际内分泌代谢杂志,2021,41(06):578.[doi:10.3760/cma.j.cn121383-20210915-09046]
Chen Shuang,Yang Tao,Gu Yong..Diagnosis and immunotherapy of type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2021,41(01):578.[doi:10.3760/cma.j.cn121383-20210915-09046]
[10]齐晓洁,苏恒.1型糖尿病的二级预防临床研究进展[J].国际内分泌代谢杂志,2022,42(03):187.[doi:10.3760/cma.j.cn121383-20210129-01088]
Qi Xiaojie,Su Heng..Progress in secondary prevention of type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2022,42(01):187.[doi:10.3760/cma.j.cn121383-20210129-01088]